From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, ...

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...

Robert F. Kennedy, Jr, the nominee for Secretary of HHS, has made promises about the status of his stake in anti-vaccine nonprofits and notable pharma companies as his confirmation hearing approaches.

Robert F. Kennedy Jr., HHS secretary nominee, faces criticism for financial ties to vaccine lawsuits, raising ethical concerns over regulatory impartiality.

Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...